U.S. bans Indian drugmaker Divi's factory, shares hit 3-year low


U.S. health regulators have banned a drug production site in India belonging to Divi's Laboratories Ltd due to manufacturing violations, sending the company's shares down to a near three-year low on Wednesday. This comes at a time when an increasingly protectionist stance by U.S. President Donald Trump is threatening to make the operating environment tougher for India's drugmakers that supply nearly a third of the medicines sold in the United States - the world's largest healthcare market.



from Biotech News